RT Journal Article SR Electronic T1 Epidemiologic, Clinical, and Biological Characteristics of Adult T-cell Leukemia / Lymphoma in Martinique (1983-2013) JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.15.20126599 DO 10.1101/2020.07.15.20126599 A1 Plumelle Yves A1 Michel Stephane A1 Delaunay Christine A1 Kone Moumouni A1 Meniane Jean-Côme A1 Christian Derancourt A1 Merle Harold A1 Molinié Vincent A1 Panelatti Gérard YR 2020 UL http://medrxiv.org/content/early/2020/07/23/2020.07.15.20126599.abstract AB We report one of the largest non-Japanese cohorts of adult T-cell leukemia/lymphoma (ATL). A total of 175 cases were identified in Martinique between 1983 and 2013. The sex ratio was 1.01. The median age was 56 years. The overall incidence rate was 1.16/105 inhabitants/year, with a risk 1.29 times higher for men. The distribution of clinical types (acute, lymphoma, and chronic) was 62.9%, 29.1%, and 8%, respectively. Median survival time was 3.06, 8.13, and 45.16 months, respectively, for the acute, lymphoma, and chronic types (p <0.001). Survival was significantly higher for lymphoma type with skin lesions (median 13.96 months versus 6.06, p <0.002) and for the acute type without hypercalcemia (5.1 versus 2.4 months, p <0.01). Symptoms associated with hypercalcemia present in 46.9% of patients and skin lesions in 43.4% were the best-performing clinical signs for the diagnosis of ATL. However, only 16.9% had these manifestations. Strongyloïdes stercoralis infection was documented in 42.5% of patients. Twenty-three patients had an atypical phenotype, including 14 cases with CD4-CD8- and 4 with CD4+CD8+. Twenty-four patients did not express CD25 with no significant impact on overall survival. The hyperploidy, trisomy of chromosome 3 and rearrangements of chromosome 14 were the most frequent karyotype abnormalities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors and their institution at any time received payment or services from a third party for any aspect of the submitted work. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University Hospital Center of Martinique. The IRB of CHUM issued a favorable opinion, reference 2020/061All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI declare the disponibility of all data referred to in the manuscript